Global Immunoglobulin E (IgE) Allergy Blood Tests Market Report 2024

The immunoglobulin E (IgE) allergy blood tests market size has grown strongly in recent years. It will grow from $30.68 billion in 2023 to $33.24 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth observed during the historic period can be attributed to several factors, including technological advancements, a higher prevalence of allergies, increased demand for personalized medicine, the expansion of healthcare infrastructure, and a growing awareness regarding allergy diagnosis and treatment.

The immunoglobulin E (IgE) allergy blood tests market size is expected to see strong growth in the next few years. It will grow to $46.23 billion in 2028 at a compound annual growth rate (CAGR) of 8.6%. The projected growth in the forecast period can be linked to various factors, including increased investments in allergy research and development, wider acceptance of point-of-care testing, heightened emphasis on early diagnosis and intervention, a surge in demand for comprehensive allergy profiling, and the integration of artificial intelligence in allergy diagnostics. Key trends expected during this period encompass the emergence of multiplex allergy testing, the utilization of telemedicine for allergy consultations, the development of novel biomarkers for allergic diseases, the expansion of direct-to-consumer allergy testing services, and the integration of big data analytics for personalized allergy management.

The increasing prevalence of allergies is anticipated to drive the growth of the IgE allergy blood tests market. Allergies occur when the immune system reacts excessively to substances typically harmless to most people, resulting in symptoms such as sneezing, itching, or respiratory issues. Lifestyle changes, environmental pollution, and genetic factors contribute to the rise in allergy cases. IgE allergy blood tests help identify specific allergens by measuring Immunoglobulin E (IgE) antibody levels in the blood, aiding in the diagnosis and management of allergic conditions such as asthma, allergic rhinitis, and food allergies. For instance, research published by Elsevier revealed an increase in food allergen-related recalls in the UK from 82 in 2020 to 84 in 2021, underscoring the driving force behind the IgE allergy blood tests market's growth.

Innovations in the IgE allergy blood test market focus on developing AI-powered allergy tests to enhance accuracy, efficiency, and scalability in allergy diagnostics. These tests leverage artificial intelligence algorithms and machine learning techniques to analyze allergy-related data and provide valuable insights into individual allergic sensitivities. For example, Dr. Dangs Lab introduced 'Allergynius Dx,' a molecular allergy diagnostics test based on Microarray using Nano Particles, capable of testing 163 food and respiratory allergens. This advancement signifies a significant leap in allergy testing, offering a comprehensive approach to identifying and managing allergies across a broad spectrum of allergens.

In May 2021, PerkinElmer Inc. acquired Immunodiagnostic Systems Holdings PLC for approximately $155 million, aiming to enhance its presence in immunodiagnostics. This acquisition combines PerkinElmer's channel expertise and testing capabilities with IDS's chemiluminescence products in endocrinology, autoimmunity, and infectious diseases, further strengthening its position in the IgE testing market. Immunodiagnostic Systems Holdings PLC specializes in fully automated quantitative assays using the IDS-iSYS multi-discipline automated system.

Major companies operating in the immunoglobulin E (IgE) allergy blood tests market are Roche Holdings Inc., Thermo Fisher Scientific Inc, Abbott Laboratories, Novartis AG, Siemens Healthineers Pvt Ltd, BD Biosciences, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, BioMérieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Bio-Techne Corporation, GenScript Biotech Corporation, Randox Laboratories Ltd, Neogen Corporation, Invitae Corporation, Quanterix Corporation, Omega Diagnostics Plc, AESKU Group GmbH, Hitachi Chemical Diagnostics Inc., HYCOR Biomedical LLC, Amerimmune LLC.

North America was the largest region in the immunoglobulin E (IgE) allergy blood tests market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulin E (IgE) allergy blood tests market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunoglobulin E (IgE) allergy blood tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Immunoglobulin E (IgE) allergy blood tests are designed to measure the levels of IgE antibodies present in the bloodstream, which are generated by the immune system in response to allergens. These tests play a crucial role in identifying the particular allergens responsible for triggering allergic reactions in individuals. Healthcare providers rely on these test results to pinpoint the allergens causing allergic symptoms, enabling them to tailor treatment plans accordingly and thereby improving patient management and overall quality of life.

The primary product categories of IgE allergy blood tests include assays and kits, which comprise enzyme-linked immunosorbent assay (ELISA) testing kits, fluorescent enzyme immunoassays (FEIA) testing kits, and chemiluminescent immunoassays (CLIA). These kits and assays consist of tools and substances utilized to analyze biological samples for specific allergens or conditions. They serve diverse applications, encompassing aero allergies, indoor allergies, outdoor allergies, food allergies, venoms, medicine allergies, and latex/metal allergies. End users of these products span diagnostic laboratories, specialty clinics, hospitals, and research and academic centers, reflecting a wide array of healthcare and scientific facilities.

The immunoglobulin E (IgE) allergy blood tests market research report is one of a series of new reports that provides immunoglobulin E (IgE) allergy blood tests market statistics, including the immunoglobulin E (IgE) allergy blood tests industry global market size, regional shares, competitors with immunoglobulin E (IgE) allergy blood tests market share, detailed immunoglobulin E (IgE) allergy blood tests market segments, market trends, and opportunities, and any further data you may need to thrive in the immunoglobulin E (IgE) allergy blood tests industry. This immunoglobulin E (IgE) allergy blood tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunoglobulin E (IgE) allergy blood tests market consists of sales of custom panels, and component-resolved diagnostics (CRD). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.